March 23, 2021: A black box warning is needed, should be prominently displayed, and should include warnings about off-label uses as well as approved indications and well-trained providers.
Read More »On Medical Treatments & Products
Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee on Johnson & Johnson COVID Vaccine
February 26, 2021: The Johnson & Johnson vaccine seems to be effective, but not proven to be more effective for moderate or severe COVID than the Pfizer or Moderna vaccines. We asked FDA to stop the hype and require studies to continue.
Read More »NCHR’s Statement on Keytruda for Early Stage Triple Negative Breast Cancer
February 9, 2021: We agree with FDA scientists that Keytruda is not proven to be effective for women with early stage triple negative breast cancer, but can cause serious health problems.
Read More »Dr. Diana Zuckerman’s Testimony on Moderna’s COVID Vaccine Before the FDA Advisory Committee
December 17, 2020: We need at least 1 year of blinded, randomized, controlled data. We agree that FDA should delay access to vaccines by members of the placebo group unless they are in priority populations.
Read More »NCHR’s Comments Regarding Spironolactone for Heart Failure with Preserved Ejection Fraction
December 16, 2020: What can be done to improve the quality of the data prior to FDA making a decision about whether or not to approve a new indication for spironolactone?
Read More »